Amati AIM VCT (AMAT) Competitors

Alliance Pharma (LON:APH) and Amati AIM VCT (LON:AMAT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings, community ranking and dividends.

Does the media refer more to APH or AMAT?

In the previous week, Alliance Pharma had 1 more articles in the media than Amati AIM VCT. MarketBeat recorded 1 mentions for Alliance Pharma and 0 mentions for Amati AIM VCT. Alliance Pharma's average media sentiment score of 0.00 equaled Amati AIM VCT'saverage media sentiment score.

Company	Overall Sentiment
Alliance Pharma	Neutral
Amati AIM VCT	Neutral

Is APH or AMAT a better dividend stock?

Alliance Pharma pays an annual dividend of GBX 2 per share and has a dividend yield of 3.3%. Amati AIM VCT pays an annual dividend of GBX 5 per share and has a dividend yield of 7.0%. Alliance Pharma pays out -3,333.3% of its earnings in the form of a dividend. Amati AIM VCT pays out -7,142.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amati AIM VCT is clearly the better dividend stock, given its higher yield and lower payout ratio.

Do analysts recommend APH or AMAT?

Alliance Pharma presently has a consensus price target of GBX 60, suggesting a potential downside of 1.80%. Given Alliance Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe Alliance Pharma is more favorable than Amati AIM VCT.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alliance Pharma	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Amati AIM VCT	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Is APH or AMAT more profitable?

Amati AIM VCT has a net margin of 0.00% compared to Alliance Pharma's net margin of -18.34%. Amati AIM VCT's return on equity of -7.38% beat Alliance Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alliance Pharma	-18.34%	-13.44%	5.98%
Amati AIM VCT	N/A	-7.38%	-4.56%

Does the MarketBeat Community favor APH or AMAT?

Alliance Pharma received 186 more outperform votes than Amati AIM VCT when rated by MarketBeat users. However, 70.83% of users gave Amati AIM VCT an outperform vote while only 62.08% of users gave Alliance Pharma an outperform vote.

Company	Underperform	Outperform
Alliance Pharma	Outperform Votes 203 62.08%	Underperform Votes 124 37.92%
Amati AIM VCT	Outperform Votes 17 70.83%	Underperform Votes 7 29.17%

Do insiders and institutionals believe in APH or AMAT?

66.3% of Alliance Pharma shares are owned by institutional investors. 12.0% of Alliance Pharma shares are owned by company insiders. Comparatively, 0.5% of Amati AIM VCT shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Which has more risk & volatility, APH or AMAT?

Alliance Pharma has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, Amati AIM VCT has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.

Which has better earnings & valuation, APH or AMAT?

Amati AIM VCT has lower revenue, but higher earnings than Alliance Pharma. Alliance Pharma is trading at a lower price-to-earnings ratio than Amati AIM VCT, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alliance Pharma	£183.15M	1.80	-£33.58M	-£0.06	-1,018.33
Amati AIM VCT	-£8M	-13.09	-£10.96M	-£0.07	-1,014.29

Summary

Alliance Pharma beats Amati AIM VCT on 12 of the 19 factors compared between the two stocks.